Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sofgen Pharma's Enterprise Value is $0.00 Mil.
Sofgen Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $74.84 Mil. Therefore, Sofgen Pharma's EV-to-FCF for today is 0.00.
The historical rank and industry rank for Sofgen Pharma's EV-to-FCF or its related term are showing as below:
During the past 6 years, the highest EV-to-FCF of Sofgen Pharma was 162.05. The lowest was -95.16. And the median was 15.65.
PRCWF's EV-to-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 19.75 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sofgen Pharma's PE Ratio (TTM) for today is calculated as:
Sofgen Pharma's share price for today is $0.0002.
Sofgen Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sofgen Pharma EV-to-FCF Related Terms
Sofgen Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sofgen Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sofgen Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sofgen Pharma EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sofgen Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sofgen Pharma's EV-to-FCF falls into.
Sofgen Pharma's current Enterprise Value is $0.00 Mil.
Sofgen Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $74.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sofgen Pharma (PRCWF) has a EV-to-FCF of 0.00 as of Sep. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sofgen Pharma and its competitors.
Is Sofgen Pharma's EV-to-FCF too high?
Sofgen Pharma's current EV-to-FCF is 0.00. Overall, Sofgen Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sofgen Pharma's EV-to-FCF compare to BKUH and ORGO?
Sofgen Pharma's EV-to-FCF of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-FCF is 19.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.75, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sofgen Pharma and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sofgen Pharma's current EV-to-FCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sofgen Pharma stock overvalued right now?
Sofgen Pharma (PRCWF) has a current EV-to-FCF of 0.00. The current EV-to-FCF is 0.00. Sofgen Pharma's overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sofgen Pharma (PRCWF), the current EV-to-FCF is 0.00 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Procaps Group SA is an integrated healthcare and pharmaceutical company that develops and manufactures pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The company's segment includes NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. It generates maximum revenue from the NextGel segment. It has geographic presence in Bolivia, Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, and the United States.
24GF Score
Get the complete analysis for PRCWF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCWF has been successfully added to your 
